English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18033/20233 (89%)
造訪人次 : 23239028      線上人數 : 374
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/31592


    標題: Clinical Benefit of Appropriate Empirical Fluoroquinolone Therapy for Adults with Community-Onset Bacteremia in Comparison with Third-Generation-Cephalosporin Therapy
    作者: Lee, Ching-Chi
    Wang, Jiun-Ling
    Lee, Chung-Hsun
    Hsieh, Chih-Chia
    Hung, Yuan-Pin
    Hong, Ming-Yuan
    Tang, Hung-Jen
    Ko, Wen-Chien
    貢獻者: Madou Sin Lau Hosp, Dept Internal Med, Div Crit Care Med
    Chang Jung Christian Univ, Grad Inst Med Sci, Coll Hlth Sci
    Natl Cheng Kung Univ, Dept Internal Med,Natl Cheng Kung Univ Hosp, Coll Med
    Natl Cheng Kung Univ, Dept Med, Coll Med
    Natl Cheng Kung Univ, Dept Emergency Med,Natl Cheng Kung Univ Hosp, Coll Med
    Minist Hlth & Welf, Dept Internal Med, Tainan Hosp
    Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    關鍵字: fluoroquinolone
    third-generation cephalosporin
    empirical therapy
    community onset
    bacteremia
    defervescence
    日期: 2017-02
    上傳時間: 2018-11-30 15:49:28 (UTC+8)
    出版者: Amer Soc Microbiology
    摘要: Both fluoroquinolones (FQs) and third-generation cephalosporins (3rd-GCs) are commonly prescribed to treat bloodstream infections, but comparative efficacies between them were rarely studied. Demographics and clinical characteristics of 733 adults with polymicrobial or monomicrobial community-onset bacteremia empirically treated by an appropriate FQ (n = 87) or 3rd-GC (n = 646) were compared. A critical illness (respectively, 8.0% versus 19.0%; P = 0.01), an initial syndrome with severe sepsis (33.3% versus 50.3%; P = 0.003), or a fatal outcome at 28 days (4.6% versus 10.5%; P = 0.08) was less common in the FQ group. A total of 645 (88.0%) patients were febrile at initial presentation, and the FQ group with (FQ group versus 3rd-GC group, respectively, 7.6 days versus 12.0 days; P = 0.04) and without (3.8 days versus 5.4 days; P = 0.001) a critical illness had a shorter time to defervescence than the 3rd-GC group. By the propensity scores, 87 patients with appropriate FQ therapy were matched with 435 treated by 3rd-GC therapy at a ratio of 1: 5, and there were no significant differences in terms of bacteremia severity, comorbidity severity, major comorbidities, causative microorganisms, and bacteremia sources between groups. Moreover, crude mortality rates at 28 days (FQ group versus 3rd-GC group, respectively, 4.6% versus 7.8%; P = 0.29) did not differ significantly. However, the time to defervescence was shorter in the FQ group (4.2 +/- 3.6 versus 6.2 +/- 7.6 days; P = 0.001). Conclusively in the adults with community-onset bacteremia, appropriate empirical FQ therapy was related to shorter time to defervescence than with 3rd-GC therapy, at least for those without a critical illness.
    關聯: Antimicrobial Agents and Chemotherapy, v.61, n.2, e02174-16
    顯示於類別:[保健營養系(所) ] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    e02174-16.full.pdf605KbAdobe PDF0檢視/開啟
    index.html0KbHTML1079檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋